PMID- 22853757
OWN - NLM
STAT- MEDLINE
DCOM- 20121123
LR  - 20220408
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 4
IP  - 7
DP  - 2012 Jul
TI  - Dendritic cell engineering for tumor immunotherapy: from biology to clinical 
      translation.
PG  - 703-18
LID - 10.2217/imt.12.40 [doi]
AB  - Dendritic cells (DCs) are the most potent APCs, with the ability to orchestrate a 
      repertoire of immune responses. DCs play a pivotal role in the initiation, 
      programming and regulation of tumor-specific immune responses, as they are poised 
      to take up, process and present tumor antigens to naive or effector T 
      lymphocytes. Although, to an extent, DC-based immunotherapeutic strategies have 
      successfully induced specific anti-tumor responses in animal models, their 
      clinical efficacy has rarely been translated into the clinic. This article 
      attempts to present a complete picture of recent developments of DC-based 
      therapeutic strategies addressing multiple components of tumor immunoenvironment. 
      It also showcases certain practical intricacies in order to explore novel 
      strategies for providing new impetus to DC-based cancer vaccination.
FAU - Bhargava, Arpit
AU  - Bhargava A
AD  - Division of Translational Research, Tata Memorial Centre, ACTREC, India.
FAU - Mishra, Dinesh
AU  - Mishra D
FAU - Banerjee, Smita
AU  - Banerjee S
FAU - Mishra, Pradyumna Kumar
AU  - Mishra PK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/immunology
MH  - *Cancer Vaccines
MH  - *Cell Engineering
MH  - Dendritic Cells/*immunology/*transplantation
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Lymphocyte Activation
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/*immunology
MH  - Translational Research, Biomedical
MH  - Tumor Microenvironment
EDAT- 2012/08/03 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/08/03 06:00
PHST- 2012/08/03 06:00 [entrez]
PHST- 2012/08/03 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.2217/imt.12.40 [doi]
PST - ppublish
SO  - Immunotherapy. 2012 Jul;4(7):703-18. doi: 10.2217/imt.12.40.